These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9529110)

  • 1. MrpB functions as the terminator for assembly of Proteus mirabilis mannose-resistant Proteus-like fimbriae.
    Li X; Mobley HL
    Infect Immun; 1998 Apr; 66(4):1759-63. PubMed ID: 9529110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Requirement of MrpH for mannose-resistant Proteus-like fimbria-mediated hemagglutination by Proteus mirabilis.
    Li X; Johnson DE; Mobley HL
    Infect Immun; 1999 Jun; 67(6):2822-33. PubMed ID: 10338487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteus mirabilis MR/P fimbriae: molecular cloning, expression, and nucleotide sequence of the major fimbrial subunit gene.
    Bahrani FK; Mobley HL
    J Bacteriol; 1993 Jan; 175(2):457-64. PubMed ID: 8093447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteus mirabilis mannose-resistant, Proteus-like fimbriae: MrpG is located at the fimbrial tip and is required for fimbrial assembly.
    Li X; Zhao H; Geymonat L; Bahrani F; Johnson DE; Mobley HL
    Infect Immun; 1997 Apr; 65(4):1327-34. PubMed ID: 9119470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mannose-resistant Proteus-like fimbriae are produced by most Proteus mirabilis strains infecting the urinary tract, dictate the in vivo localization of bacteria, and contribute to biofilm formation.
    Jansen AM; Lockatell V; Johnson DE; Mobley HL
    Infect Immun; 2004 Dec; 72(12):7294-305. PubMed ID: 15557655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mannose-resistant Proteus-like and P. mirabilis fimbriae have specific and additive roles in P. mirabilis urinary tract infections.
    Zunino P; Sosa V; Schlapp G; Allen AG; Preston A; Maskell DJ
    FEMS Immunol Med Microbiol; 2007 Oct; 51(1):125-33. PubMed ID: 17854474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteus mirabilis MR/P fimbrial operon: genetic organization, nucleotide sequence, and conditions for expression.
    Bahrani FK; Mobley HL
    J Bacteriol; 1994 Jun; 176(11):3412-9. PubMed ID: 7910820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo phase variation of MR/P fimbrial gene expression in Proteus mirabilis infecting the urinary tract.
    Zhao H; Li X; Johnson DE; Blomfield I; Mobley HL
    Mol Microbiol; 1997 Mar; 23(5):1009-19. PubMed ID: 9076737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction of an MR/P fimbrial mutant of Proteus mirabilis: role in virulence in a mouse model of ascending urinary tract infection.
    Bahrani FK; Massad G; Lockatell CV; Johnson DE; Russell RG; Warren JW; Mobley HL
    Infect Immun; 1994 Aug; 62(8):3363-71. PubMed ID: 7913698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fimbriae of uropathogenic Proteus mirabilis.
    Rocha SP; Pelayo JS; Elias WP
    FEMS Immunol Med Microbiol; 2007 Oct; 51(1):1-7. PubMed ID: 17640292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using Hemagglutination, Surface Shearing, and Acid Treatment to Study Fimbriae in Proteus mirabilis.
    Himpsl SD; Pearson MM; Mobley HLT
    Methods Mol Biol; 2019; 2021():109-120. PubMed ID: 31309500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteus mirabilis fimbriae: N-terminal amino acid sequence of a major fimbrial subunit and nucleotide sequences of the genes from two strains.
    Bahrani FK; Cook S; Hull RA; Massad G; Mobley HL
    Infect Immun; 1993 Mar; 61(3):884-91. PubMed ID: 8094384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repression of bacterial motility by a novel fimbrial gene product.
    Li X; Rasko DA; Lockatell CV; Johnson DE; Mobley HL
    EMBO J; 2001 Sep; 20(17):4854-62. PubMed ID: 11532949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of MrpI as the sole recombinase that regulates the phase variation of MR/P fimbria, a bladder colonization factor of uropathogenic Proteus mirabilis.
    Li X; Lockatell CV; Johnson DE; Mobley HL
    Mol Microbiol; 2002 Aug; 45(3):865-74. PubMed ID: 12139630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteus mirabilis fimbriae: construction of an isogenic pmfA mutant and analysis of virulence in a CBA mouse model of ascending urinary tract infection.
    Massad G; Lockatell CV; Johnson DE; Mobley HL
    Infect Immun; 1994 Feb; 62(2):536-42. PubMed ID: 7905463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fimbriae have distinguishable roles in Proteus mirabilis biofilm formation.
    Scavone P; Iribarnegaray V; Caetano AL; Schlapp G; Härtel S; Zunino P
    Pathog Dis; 2016 Jul; 74(5):. PubMed ID: 27091004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteus mirabilis fimbriae: identification, isolation, and characterization of a new ambient-temperature fimbria.
    Massad G; Bahrani FK; Mobley HL
    Infect Immun; 1994 May; 62(5):1989-94. PubMed ID: 7909538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of polyphosphate kinase in virulence and stress tolerance of uropathogenic Proteus mirabilis.
    Peng L; Jiang Q; Pan JY; Deng C; Yu JY; Wu XM; Huang SH; Deng XY
    Med Microbiol Immunol; 2016 Apr; 205(2):97-109. PubMed ID: 26233310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue-binding affinity of Proteus mirabilis fimbriae in the human urinary tract.
    Sareneva T; Holthöfer H; Korhonen TK
    Infect Immun; 1990 Oct; 58(10):3330-6. PubMed ID: 1976113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New aspects of the role of MR/P fimbriae in Proteus mirabilis urinary tract infection.
    Zunino P; Geymonat L; Allen AG; Preston A; Sosa V; Maskell DJ
    FEMS Immunol Med Microbiol; 2001 Aug; 31(2):113-20. PubMed ID: 11549418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.